報價延遲最少15分鐘:2026/03/05 21:18 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.31 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.98/-1.06
|
|
企業價值
654.06M
|
| 資產負債 |
|
每股賬面淨值
1.40
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts. |
